MN Cannabis at Work: Employer Rules After 2023

What did August 2023 actually change for Minnesota workplace policies?

August 2023 split Minnesota workplace controlled-substances law into two separate regimes. Cannabis is no longer a “drug” under DATWA. Minn. Stat. § 181.950, subd. 4 defines “drug” as a Schedule controlled substance under § 152.01, subd. 4, “but does not include marijuana, tetrahydrocannabinols, cannabis flower, cannabis products, lower-potency hemp edibles, or hemp-derived consumer products.” A standalone “cannabis testing” definition lives at § 181.950, subd. 5a. The general DATWA drug-testing definition expressly does not include cannabis testing “unless stated otherwise.”

That definitional split matters. A pre-2023 written policy that lumps cannabis into a generic “drug testing” section now misstates the statute. The DATWA categories the policy must cover for cannabis (random testing, reasonable-suspicion testing, applicant testing, work rules, adverse-action procedure) all sit on different statutory ground than the same categories for traditional drugs. A policy rewrite that does not carry forward the separation is a policy with a structural defect, and the defect typically surfaces only when an employer attempts to discharge an employee for a positive cannabis test on a pre-2023 template.

In my practice, the recurring sticking point in cannabis discharge disputes is that the employer’s policy still references cannabis as a “drug” or “controlled substance.” The discharge then has to be defended against a statute that says it is not. Rewriting against the post-2023 framework is the cheapest fix; defending the old policy in a § 181.956 action with attorney-fee exposure is the expensive one. Coordinating the rewrite with adjacent rules like PTO payout and retaliation protections keeps the handbook consistent.

What does the Lawful Consumable Products Act protect off the job?

The Lawful Consumable Products Act (“LCPA”), Minn. Stat. § 181.938, is the off-duty shield. The statute prohibits an employer from refusing to hire a job applicant or disciplining or discharging an employee “because the applicant or employee engages in or has engaged in the use or enjoyment of lawful consumable products, if the use or enjoyment takes place off the premises of the employer during nonworking hours.” The 2023 amendment added cannabis flower, cannabis products, lower-potency hemp edibles, and hemp-derived consumer products to the LCPA’s protected list, alongside food, alcohol, and tobacco. § 181.938, subd. 2(a).

The statute then closes a federal loophole. Subdivision 2(b) provides that cannabis flower, cannabis products, lower-potency hemp edibles, and hemp-derived consumer products “are lawful consumable products for the purpose of Minnesota law, regardless of whether federal or other state law considers cannabis use, possession, impairment, sale, or transfer to be unlawful.” Federal Schedule I status does not let a Minnesota employer rely on federal illegality to discipline off-duty use that took place lawfully under Minnesota law.

The LCPA’s only carve-outs are narrow. Subdivision 3 permits a restriction that “relates to a bona fide occupational requirement and is reasonably related to the employment activities or responsibilities of a particular employee or group of employees” or “is necessary to avoid a conflict of interest with any responsibilities owed by the employee to the employer, or the appearance of such a conflict of interest.” Health and life insurance plans may also reflect actual differential cost based on use. The remedy in subd. 4 is a damages-only action limited to “wages and benefits lost by the individual because of the violation,” with attorney fees to a prevailing party.

Where does Minnesota law let an employer draw the on-the-job line?

The on-the-job line is drawn at three triggers: working time, employer premises, and employer equipment. Under Minn. Stat. § 181.952, subd. 3, an employer may enact work rules prohibiting “cannabis flower, cannabis product, lower-potency hemp edible, and hemp-derived consumer product use, possession, impairment, sale, or transfer while an employee is working or while an employee is on the employer’s premises or operating the employer’s vehicle, machinery, or equipment.” Outside those three triggers, the LCPA off-duty shield controls.

Three operational points come up most often.

Premises. The rule reaches employer-owned property whether or not the employee is working, including parking lots, break areas, and storage rooms. An employer can prohibit possession in a locked vehicle on a company parking lot.

Equipment. The equipment rule covers company vehicles, machinery, and tools wherever they are located. A company truck on a public street remains a place where the rule applies. The reach matters for service businesses where the employee is rarely at a fixed employer site but is regularly operating employer-owned equipment.

Off-premises business travel. A hotel room rented in the employer’s name is not the employer’s premises; a customer’s job site often is “employer premises” by extension. Drafting the rule with “while working” language rather than a static premises map closes the gap.

The work rule itself must live inside a DATWA-compliant written policy meeting the § 181.952, subd. 1 six-element minimum. A handbook bullet on cannabis that does not sit inside a compliant testing policy cannot support discharge based on a positive test.

How is “cannabis impairment” measured under Minnesota law?

Cannabis impairment is measured against a statutory standard distinct from any laboratory result. Under Minn. Stat. § 181.953, subd. 10a(1), an employer may take adverse action “if, as the result of consuming cannabis flower, a cannabis product, a lower-potency hemp edible, or a hemp-derived consumer product, the employee does not possess that clearness of intellect and control of self that the employee otherwise would have.” That phrase, “clearness of intellect and control of self,” is the operative test. The alternative trigger in subd. 10a(2) is a confirmatory cannabis test result, but for non-excepted positions the test is rarely the route in.

Two practical consequences flow from the standard.

First, a body-fluid result that shows the presence of cannabis metabolites does not by itself prove impairment. THC metabolites can persist for days or weeks after use, long after any acute impairment has passed. An employer relying solely on a positive metabolite result to support a non-excepted-position discharge is relying on data that does not match the statutory question.

Second, the impairment standard is observable, not chemical. The supporting evidence is what a trained supervisor saw and documented at the time, not what a lab returned three days later. The lab confirms that cannabis was consumed; the supervisor’s notes are what tie the consumption to the on-the-job condition that the statute makes actionable.

What does cannabis “reasonable suspicion” look like in practice?

Cannabis reasonable suspicion, like every other DATWA reasonable-suspicion category, requires “specific facts and rational inferences drawn from those facts.” Minn. Stat. § 181.950, subd. 12. What makes cannabis distinct is the absence of a roadside-style test analog. Alcohol has breath, eye-pattern, and field-test markers cross-validated against blood-alcohol concentration. Cannabis does not. A supervisor who calls in a reasonable-suspicion test on cannabis is relying on observation, not on a quick-confirmation field instrument.

What I see hold up under § 181.956 challenge: contemporaneous notes from a trained supervisor describing observed speech, coordination, eye appearance, smell, behavior, and the deviation from the employee’s baseline. A second observer’s confirmation. A short, factual incident report written within hours, not reconstructed from memory days later. A direct connection between the observation and on-the-job conduct, not a generalized “the employee seemed off.”

What I see fail: a single physical marker (red eyes, slowed speech) treated as sufficient on its own; a supervisor’s report written after the test result came back; a reasonable-suspicion call based on third-hand reports of off-duty use; or a single observation by an untrained observer with no baseline comparison. In a workplace where cannabis discipline is a foreseeable scenario, supervisor training on the impairment standard is the highest-return policy investment.

Which Minnesota positions actually permit cannabis testing?

Cannabis testing is permitted only for the seven categories enumerated in Minn. Stat. § 181.951, subd. 9: a safety-sensitive position; a peace officer position; a firefighter position; a position requiring face-to-face care, training, education, supervision, counseling, consultation, or medical assistance to children, vulnerable adults, or patients receiving health care services; a position requiring a commercial driver’s license or motor-vehicle operation where state or federal law requires drug or alcohol testing; a position funded by a federal grant; or any other position for which state or federal law specifically requires cannabis testing.

The applicant rule in § 181.951, subd. 8 is a hard floor: an employer “must not request or require a job applicant to undergo cannabis testing as a condition of employment unless otherwise required by state or federal law.” An applicant for a non-excepted role cannot be cannabis-tested at all, and refusal to hire based on a positive cannabis test taken voluntarily by the applicant is independently barred.

The most aggressive over-designation pattern I see is treating ordinary office, sales, or administrative roles as “safety-sensitive” because the employee occasionally drives between offices or lifts a box. The label has a statutory meaning under § 181.950, subd. 13: the position must be one “in which an impairment caused by drug, alcohol, or cannabis usage would threaten the health or safety of any person.” Stretching it is the dominant cause of cannabis-testing program failures, because a successful challenge invalidates the random-testing pool for the entire class.

How do federal rules override Minnesota cannabis legalization for some workers?

Federal law continues to treat cannabis as a Schedule I controlled substance under the Controlled Substances Act, and that classification reaches several employer categories where Minnesota legalization is preempted. 49 C.F.R. § 382.213(a) tells the most common Minnesota employer story: “No driver shall report for duty or remain on duty requiring the performance of safety-sensitive functions when the driver uses any drug or substance identified in 21 CFR 1308.11 Schedule I.” Schedule I includes marijuana. The DOT testing rule applies regardless of state legalization, and the U.S. Department of Transportation has confirmed in public guidance that medical or recreational state authorization is not a defense.

Four federal-override categories come up most for Minnesota employers:

1. Commercial driver’s license positions subject to 49 C.F.R. Part 382 testing.
2. Federal contractors subject to the Drug-Free Workplace Act, 41 U.S.C. § 8101 et seq.
3. Federal grant recipients for whom federal grant terms require a cannabis-tested workforce.
4. Federally regulated industries (FAA-regulated aviation, USCG-regulated maritime, NRC-regulated nuclear) with their own controlled-substance rules.

In each, federal law sets a floor that Minnesota legalization cannot lower, and DATWA’s § 181.957 preemption section preserves the federal program’s scope. A Minnesota employer with even one CDL driver almost always runs two parallel programs: a DOT-compliant program for the regulated drivers and a DATWA-compliant program for everyone else. Mixing them is the dominant compliance failure pattern.

Does Minnesota’s medical cannabis program create separate accommodation duties?

The medical-cannabis employment provisions that previously lived at Minn. Stat. § 152.32 were repealed effective December 1, 2025, when the medical program was folded into the Chapter 342 regulatory framework. A registered medical-cannabis patient is now treated, for workplace-rules purposes, the same as any other adult cannabis user under the LCPA, DATWA, and the cannabis-testing rules described above. The employer-side analysis no longer turns on a separate medical-patient-specific anti-discrimination provision.

What did not change is the disability-accommodation overlay. The underlying medical condition that led the patient to register is itself often an actual or perceived disability under the Minnesota Human Rights Act, Minn. Stat. § 363A, and an accommodation request tied to the condition (modified schedule, telework, transfer of duties) still triggers the standard interactive-process duty. That overlay is fact-specific and does not require an employer to permit on-duty cannabis use. For broader context on how disability claims interact with substance use, see alcoholism and drug addiction as protected disabilities.

The practical drafting point: a 2023 or 2024 handbook section that recites the old § 152.32 medical-cannabis presumption is now stale. Strike the section, replace it with a cross-reference to the LCPA off-duty shield and the cannabis-testing rules, and route any disability-accommodation request through the standard interactive-process channel.

How do you write a workplace cannabis policy that holds up?

A defensible Minnesota workplace cannabis policy carries seven elements. None is optional, and each tracks a statute the policy will be measured against if challenged. Most pre-2023 templates miss two or three of them, and a missing element is a frequent reason a cannabis-related discharge cannot be defended without paying both the claim and attorney fees. The list below is the drafting checklist I run when an employer asks for a clean rewrite rather than a patch.

1. Separation from “drug” testing. The cannabis sections sit in their own block, citing § 181.950 subd. 5a’s separate cannabis-testing definition, not under a generic “drug” heading.
2. Six DATWA elements. The cannabis work rule and any cannabis testing both live inside a § 181.952, subd. 1 policy that includes the persons subject to testing, the circumstances under which testing may be required, the right to refuse with consequences, the disciplinary action that may follow a confirmatory positive, the right to explain or pay for a retest, and any appeal procedures.
3. On-the-job line. A § 181.952, subd. 3 work rule prohibiting use, possession, impairment, sale, or transfer while working, on premises, or operating equipment.
4. Impairment standard. A clear “clearness of intellect and control of self” framing that tracks § 181.953, subd. 10a(1), with a non-exhaustive list of observable indicators a trained supervisor will document.
5. Position designations. A separate written designation of which positions are safety-sensitive, peace officer, firefighter, vulnerable-adult-care, CDL, or federally funded, and therefore inside the § 181.951, subd. 9 cannabis-testing exception.
6. Federal carve-out. A § 181.957 federal-preemption section identifying any DOT, federal grant, federal contractor, or federally regulated population covered by a separate compliant program.
7. Off-duty silence. An express statement that off-duty, off-premises cannabis use that does not produce on-the-job impairment is outside the policy’s reach. This is the LCPA shield restated as employer policy, and it preempts the most common employee claim.

A policy missing any one of these is missing a piece the statute will check at enforcement. The drafting work is one-time; the litigation cost of a defective policy is recurring.

How do you handle a positive cannabis test for a non-excepted employee?

The non-excepted-position cannabis-positive test is the hardest case in current Minnesota law. The position is not on the § 181.951, subd. 9 exception list, so the test itself was either voluntary or improperly administered. The body fluid showed cannabis. The supervisor saw nothing on the job. The handbook’s pre-2023 language still treats cannabis as a drug, and the supervisor wants to discharge based on the lab result alone. Three statutory rules then point in the same direction: pause before acting, because discharge on these facts will be hard to defend.

First, a positive test on a non-excepted role, without a written cannabis work rule, without on-duty impairment, and without a position falling inside the § 181.951, subd. 9 exception, generally cannot support discharge. § 181.953, subd. 10a ties cannabis adverse action to either observed loss of clearness and control or a confirmatory cannabis test for a position that is allowed to test. Neither prong fires for the non-excepted role.

Second, the LCPA shield in § 181.938 backstops the rule. Off-duty, off-premises cannabis use is protected, and a discharge premised on it (rather than on observed on-the-job impairment) creates an LCPA wages-and-benefits action with attorney fees.

Third, the DATWA first-positive rehabilitation requirement of § 181.953, subd. 10 layers on top. Even where a confirmatory cannabis test was authorized for an excepted position, the first-positive rule still requires offering counseling or rehabilitation before discharge. About half of the cannabis-discharge disputes I see involve an employer skipping the rehabilitation offer because it treated cannabis the same way it treated alcohol under the pre-2023 policy. Discharge plus a missing rehabilitation offer plus an LCPA off-duty-use claim is a familiar three-claim posture, each with its own attorney-fee exposure.

The cleanest path is to pause before discharge. Confirm the position is on the § 181.951, subd. 9 list. Confirm a § 181.952, subd. 3 cannabis work rule exists in writing. Confirm contemporaneous supervisor documentation of impairment, not just a lab result. Confirm the rehabilitation opportunity has been offered and refused or failed. If any one of those four is missing, the discharge is not yet ready to defend.

A Minnesota employer’s cannabis-related risk in 2026 is concentrated in two places: a pre-2023 policy that has not been rewritten, and a discharge decision that treats cannabis the way the policy treats traditional drugs. The statute and the DATWA framework no longer line up that way, and the off-duty shield in § 181.938 plus the impairment standard in § 181.953, subd. 10a now do most of the work.

If you’d like a second set of eyes on a planned cannabis-related discharge, a workplace policy rewrite, or a position-designation review, email [email protected] with a brief description and any current handbook language. For broader workplace-policy questions, see the employment law practice area overview, which connects cannabis policy to the rest of the Minnesota employer toolkit including final pay rules, the at-will termination framework, and non-compete alternatives.